Presenters
Professor of Clinician Scientist and Program
Prof. Merlin Thomas
Course Details
Prof. Merlin Thomas discusses about the guideline recommendation on the use of SGLT2 in T2D and CKD. Prof. Thomas provided important points on the EMPA-REG Renal Outcomes data in this video. The safety of using SGLT2i for patients with T2D + CKD was also extensively shared. This is very important as CKD in T2D patients is very high in terms of prevalence.
Estimated time of Completion: 16 Mins 55 Secs
CPD Points: 1 CPD point
Empagliflozin in T2D and CKD Course Outline
Section 1
- KDIGO recommendation of 1st line therapy in T2D + CKD
- SGLT2i slows the eGFR decline in T2D + CKD
- SGLT2i reduces serious falls in kidney function
- SGLT2i should be standard of care in patients with T2D with CKD
Section 2
- Does an SGLT2i still work in people with T2D + CKD?
- EMPA-REG Renal Trial
- SGLT2i reduces MACE in T2D + eGFR<60
- SGLT2i reduces HHF in T2D + eGFR<60
Section 3
- Is it safe to use an SGLT2 inhibitor in people with T2D + CKD?
- KDIGO: algorithm for initiation of SGLT2i therapy in T2D + CKD
- Safety of SGLT2i in patients with eGFR<60
- Empagliflozin is well tolerated in HF + CKD